ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

OPEN

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

OPEN

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

OPEN

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

OPEN

Market Review – European Generic Medicines Markets

Simon-Kucher. Policy Requirements for a Sustainable Biosimilar Market (September 2016)

skp-cover

picto-reportpicto-videopicto-pr

IMS – The Impact of Biosimilar Competition (2016)

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

IMS Institute – Biosimilar Report

IMS – The Impact of Biosimilar Competition (2015)

This document sets out to describe the effects on price, volume and market share following the arrival and presence of biosimilar competition in the European Economic Area (EEA). The document consists of a set of indicators and guidance on how to interpret these indicators. It has been prepared as a set of indicators to monitor the impact of biosimilars in the European markets. It was prepared by IMS Health at the request of the European Commission services with initial contributions from EFPIA, EGA, and EuropaBio.

EMA has a central role in setting the rules for biosimilar submissions, approving applications, establishing approved indications and monitoring adverse events, and if necessary issue safety warning. We have when appropriate quoted their information and statements.

This first report will be based on full year 2014 data; the objective thereafter is to annually publish the previous year’s updated indicators.


To read The Impact of Biosimilar Competition full report, please click here.
To read The Impact of Biosimilar Competition: Reading Guide, please click here.
To read The Impact of Biosimilar Competition: Five Observations by IMS Health, please click here.

IGES Report: Value of Generic Medicines – Health Economics Study, Berlin, 5 October 2015

IGES_report

To consult the infographics, please click here.

EGA Vision 2015

To view the full report, please click here.

IMS Health 2015: The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective, June 2015

To view the full report, click here
To view the infographic, click here